Capricor Therapeutics, based in Beverly Hills, develops biological therapies for serious medical conditions, focusing on CAP-1002 for Duchenne muscular dystrophy in Phase 3 trials. The company also utilizes exosome technology for various therapeutic applications.
Capricor Therapeutics (CAPR) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Capricor Therapeutics's actual EPS was -$0.53, missing the estimate of -$0.32 per share, resulting in a -64.09% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
